Disc Medicine Inc · News · TradingHolo

Disc Medicine Inc · News · TradingHolo

IRON news

Headlines tagged to this company

Disc Medicine Is Maintained at Overweight by Morgan Stanley

Dow Jones Newswires · 6 h ago

Disc Medicine Is Maintained at Buy by Truist Securities

Dow Jones Newswires · 8 h ago

Truist Securities maintains Buy rating on Disc Medicine, $115 price target

TradingView · 8 h ago

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones Newswires · 10 h ago

Disc Medicine, Inc. (IRON) Phase 3 Bitopertin Met All Endpoints

TradingView · 11 h ago

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

PR Newswire · 11 h ago

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

PR Newswire · 11 h ago

Disc Medicine Is Maintained at Outperform by Wedbush

Dow Jones Newswires · 11 h ago

Wedbush maintains Outperform rating on Disc Medicine, $110 price target

TradingView · 11 h ago

Disc Medicine Announces Proposed $350 Million Public Offering Of Common Stock And Pre-Funded Warrants

Reuters · 26 h ago

Disc Medicine launches $350M public offering of common stock and pre-funded warrants

Seeking Alpha · 28 h ago

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire · 28 h ago

Disc Medicine Price Target Raised to $120.00/Share From $100.00 by BMO Capital

Dow Jones Newswires · 30 h ago

Under the Radar: Disc Shares Jump as Pill for Sunlight Disorder Succeeds in Study — WSJ

Dow Jones Newswires · 32 h ago

Disc Medicine's late-stage win clears path for approval of sun-allergy pill

Reuters · 32 h ago

Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes — Barrons.com

Dow Jones Newswires · 32 h ago

Disc Medicine Shares Gain on Positive Trial Results for Erythropoietic Protoporphyria Treatment

Dow Jones Newswires · 33 h ago

Disc Medicine Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones Newswires · 33 h ago

Cantor Fitzgerald maintains Overweight rating on Disc Medicine, $170 price target

TradingView · 33 h ago

Disc Medicine's rare disease drug succeeds in late-stage trial

Reuters · 2 d ago